nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0914	0.126	CbGbCtD
Tasosartan—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.086	0.119	CbGbCtD
Tasosartan—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.086	0.119	CbGbCtD
Tasosartan—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0777	0.107	CbGbCtD
Tasosartan—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0777	0.107	CbGbCtD
Tasosartan—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0671	0.0925	CbGbCtD
Tasosartan—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0651	0.0898	CbGbCtD
Tasosartan—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0589	0.0812	CbGbCtD
Tasosartan—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0589	0.0812	CbGbCtD
Tasosartan—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0565	0.0779	CbGbCtD
Tasosartan—AGTR2—blood—acquired immunodeficiency syndrome	0.0134	0.193	CbGeAlD
Tasosartan—AGTR2—lung—acquired immunodeficiency syndrome	0.0118	0.169	CbGeAlD
Tasosartan—AGTR2—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.0118	0.058	CbGpPWpGaD
Tasosartan—AGTR1—endothelium—acquired immunodeficiency syndrome	0.00925	0.132	CbGeAlD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00914	0.045	CbGpPWpGaD
Tasosartan—AGTR1—blood plasma—acquired immunodeficiency syndrome	0.00821	0.118	CbGeAlD
Tasosartan—AGTR2—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00658	0.0324	CbGpPWpGaD
Tasosartan—AGTR2—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00618	0.0305	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00613	0.0302	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.00554	0.0273	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00501	0.0247	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00467	0.023	CbGpPWpGaD
Tasosartan—AGTR2—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00424	0.0209	CbGpPWpGaD
Tasosartan—AGTR1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00384	0.0189	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00371	0.0183	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00342	0.0169	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00336	0.0166	CbGpPWpGaD
Tasosartan—AGTR1—lymphoid tissue—acquired immunodeficiency syndrome	0.0032	0.0458	CbGeAlD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00309	0.0152	CbGpPWpGaD
Tasosartan—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00302	0.0432	CbGeAlD
Tasosartan—AGTR1—blood—acquired immunodeficiency syndrome	0.00301	0.0431	CbGeAlD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00298	0.0147	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.00291	0.0143	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.00291	0.0143	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00283	0.0139	CbGpPWpGaD
Tasosartan—AGTR1—vagina—acquired immunodeficiency syndrome	0.00279	0.04	CbGeAlD
Tasosartan—AGTR1—lung—acquired immunodeficiency syndrome	0.00264	0.0378	CbGeAlD
Tasosartan—AGTR2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.00261	0.0129	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00256	0.0126	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00245	0.0121	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00245	0.0121	CbGpPWpGaD
Tasosartan—AGTR1—nervous system—acquired immunodeficiency syndrome	0.00244	0.035	CbGeAlD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00242	0.0119	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.0024	0.0118	CbGpPWpGaD
Tasosartan—AGTR1—central nervous system—acquired immunodeficiency syndrome	0.00235	0.0337	CbGeAlD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00229	0.0113	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00228	0.0112	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00221	0.0109	CbGpPWpGaD
Tasosartan—AGTR1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00214	0.0106	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00207	0.0102	CbGpPWpGaD
Tasosartan—AGTR1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.00201	0.00993	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.002	0.00985	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00199	0.00983	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00195	0.00962	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00195	0.00962	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	0.00191	0.00943	CbGpPWpGaD
Tasosartan—AGTR1—brain—acquired immunodeficiency syndrome	0.00187	0.0267	CbGeAlD
Tasosartan—AGTR2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00187	0.0092	CbGpPWpGaD
Tasosartan—AGTR1—lymph node—acquired immunodeficiency syndrome	0.0018	0.0258	CbGeAlD
Tasosartan—AGTR1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.0018	0.00889	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00175	0.00861	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00168	0.00829	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.00163	0.00804	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00158	0.00779	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00156	0.00769	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00152	0.0075	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00149	0.00732	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00149	0.00732	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00148	0.00732	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00145	0.00715	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	0.00145	0.00714	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	0.00145	0.00714	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00142	0.00698	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	0.00141	0.00695	CbGpPWpGaD
Tasosartan—AGTR1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00138	0.00681	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	0.00138	0.00679	CbGpPWpGaD
Tasosartan—Valsartan—ALB—acquired immunodeficiency syndrome	0.00135	0.672	CrCbGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00134	0.00659	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00131	0.00647	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00121	0.00596	CbGpPWpGaD
Tasosartan—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.00116	0.0166	CbGeAlD
Tasosartan—AGTR2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00113	0.00557	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.00111	0.00549	CbGpPWpGaD
Tasosartan—CYP3A4—blood—acquired immunodeficiency syndrome	0.00111	0.0158	CbGeAlD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00109	0.00539	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00102	0.00502	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.00101	0.00497	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000948	0.00467	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000948	0.00467	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000921	0.00454	CbGpPWpGaD
Tasosartan—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000897	0.0128	CbGeAlD
Tasosartan—AGTR2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000897	0.00442	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000893	0.0044	CbGpPWpGaD
Tasosartan—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000864	0.0124	CbGeAlD
Tasosartan—AGTR2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000857	0.00423	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000857	0.00423	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	0.000852	0.0042	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00084	0.00414	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00084	0.00414	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000833	0.00411	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000811	0.004	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	0.000795	0.00392	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000789	0.00389	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000781	0.00385	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000775	0.00382	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000762	0.00376	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000762	0.00376	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	0.000757	0.00373	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000748	0.00369	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000742	0.00366	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000721	0.00355	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000676	0.00333	CbGpPWpGaD
Tasosartan—Losartan—ALB—acquired immunodeficiency syndrome	0.000657	0.328	CrCbGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.00065	0.0032	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000639	0.00315	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000636	0.00313	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000636	0.00313	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000629	0.0031	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00058	0.00286	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000575	0.00284	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000571	0.00282	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000569	0.00281	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	0.000552	0.00272	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00053	0.00261	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000523	0.00258	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000515	0.00254	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000508	0.00251	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000484	0.00239	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000484	0.00239	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000484	0.00238	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000479	0.00236	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000473	0.00233	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000461	0.00227	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00045	0.00222	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00045	0.00222	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000436	0.00215	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000428	0.00211	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000368	0.00182	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000343	0.00169	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000337	0.00166	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000332	0.00164	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000332	0.00164	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000309	0.00152	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000302	0.00149	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000292	0.00144	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000291	0.00143	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000279	0.00138	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000279	0.00138	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000274	0.00135	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000274	0.00135	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000264	0.0013	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000253	0.00125	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000248	0.00122	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000248	0.00122	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000208	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000205	0.00101	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.0002	0.000985	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000189	0.000932	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000187	0.000924	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000186	0.000918	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000178	0.000879	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000177	0.000875	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000173	0.000851	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00017	0.000839	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000156	0.000769	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000147	0.000723	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000147	0.000723	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000112	0.00055	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.00011	0.000542	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000108	0.000534	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000105	0.000517	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000101	0.000496	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.84e-05	0.000485	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	8.89e-05	0.000438	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	7.56e-05	0.000372	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.81e-05	0.000286	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.78e-05	0.000285	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.42e-05	0.000168	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.55e-05	7.64e-05	CbGpPWpGaD
